All sponsors

Sumitomo Pharma America, Inc. $4506.T

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING5
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +21.5 months). See all sponsors →

Open Sumitomo Pharma America, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Nusivertib
NCT04176198
P1/2RecruitingMyelofibrosis2402027-04-30 (+62 mo)
Enzomenib
NCT04988555
P1/2RecruitingLeukemia, Myeloid, Acute; Leukemia, Lymphocytic, Acute6062027-06-30 (+30 mo)
DSP-3077 Retinal Sheet Cohort 1
NCT06891885
P1/2RecruitingRetinitis Pigmentosa122028-10-31
SMP3124LP
NCT06526819
P1/2RecruitingSolid Tumor1202028-12
DSP-1083 implantation
NCT06753331
P1/2RecruitingParkinson's Disease252030-12-15 (+21 mo)